Literature DB >> 22309049

Mechanism of anti-platelet activity of Oligoporus tephroleucus oligoporin A: involvement of extracellular signal-regulated kinase phosphorylation and cyclic nucleotide elevation.

Ji Young Park1, Won Jun Oh, Myung Jin Kim, Tae-Hwan Kim, Jae Youl Cho, Hwa-Jin Park, In-Kyoung Lee, Suk Kim, Gon-Seop Kim, Sang-Keun Kim, Geon-Sik Seo, Bong-Sik Yun, Man Hee Rhee.   

Abstract

This study investigated the inhibitory effects of oligoporin A on platelet aggregation and the mechanism of its action on downstream signaling molecules. Oligoporin A was isolated from the fruiting bodies of Oligoporus tephroleucus (Polyporaceae). The anti-platelet activities of oligoporin A were studied using rat platelets. The effects of oligoporin A on intracellular Ca(2+) mobilization, ATP release, production of the cyclic nucleotides cAMP and cGMP, extracellular signal-regulated kinase (ERK) 2 phosphorylation, and fibrinogen binding to active integrin α(II)(b)β(3) were assessed. Oligoporin A, but not oligoporins B and C, inhibited collagen-induced platelet aggregation in a concentration-dependent manner. Interestingly, oligoporin A did not affect ADP- and thrombin-induced platelet aggregations, which act on different types of membrane receptors. Granule secretion analysis demonstrated that oligoporin A significantly and dose-dependently reduced collagen-induced ATP release and intracellular Ca(2+) mobilization. Additionally, oligoporin A induced the dynamic increase in cAMP and cGMP. Increased cGMP production was further confirmed by the simultaneous production of nitric oxide. Pretreatment with oligoporin A significantly blocked collagen-induced ERK2 phosphorylation. Finally, oligoporin A vaguely diminished the binding of fibrinogen to its cognate receptor, integrin α(II)(b)β(3). The results indicate that oligoporin A inhibits only collagen-induced platelet aggregation mediated through the modulation of downstream signaling molecules. Oligoporin A may be beneficial against cardiovascular disease provoked by aberrant platelet activation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22309049     DOI: 10.3109/09537104.2011.629309

Source DB:  PubMed          Journal:  Platelets        ISSN: 0953-7104            Impact factor:   3.862


  6 in total

Review 1.  Natural Products for Antithrombosis.

Authors:  Cen Chen; Feng-Qing Yang; Qian Zhang; Feng-Qin Wang; Yuan-Jia Hu; Zhi-Ning Xia
Journal:  Evid Based Complement Alternat Med       Date:  2015-05-17       Impact factor: 2.629

2.  Chlorin e6 Prevents ADP-Induced Platelet Aggregation by Decreasing PI3K-Akt Phosphorylation and Promoting cAMP Production.

Authors:  Ji Young Park; Hyun Dong Ji; Bo Ra Jeon; Eun Ju Im; Young Min Son; Joo Young Lee; Dong-Ha Lee; Young-Chul Lee; Eujin Hyun; Qi Jia; Mei Hong; Hwa-Jin Park; Man Hee Rhee
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-13       Impact factor: 2.629

3.  The inhibitory activity of ginsenoside Rp4 in adenosine diphosphate-induced platelet aggregation.

Authors:  Young-Min Son; Da-Hye Jeong; Hwa-Jin Park; Man-Hee Rhee
Journal:  J Ginseng Res       Date:  2016-02-15       Impact factor: 6.060

Review 4.  Coagulation System Activation for Targeting of COVID-19: Insights into Anticoagulants, Vaccine-Loaded Nanoparticles, and Hypercoagulability in COVID-19 Vaccines.

Authors:  Mohamed S Abdel-Bakky; Elham Amin; Mohamed G Ewees; Nesreen I Mahmoud; Hamdoon A Mohammed; Waleed M Altowayan; Ahmed A H Abdellatif
Journal:  Viruses       Date:  2022-01-24       Impact factor: 5.048

Review 5.  Potential clinical applications of phytopharmaceuticals for the in-patient management of coagulopathies in COVID-19.

Authors:  Ashis K Mukherjee; Dhruba J Chattopadhyay
Journal:  Phytother Res       Date:  2022-02-11       Impact factor: 6.388

6.  Antiplatelet Activity of Morus alba Leaves Extract, Mediated via Inhibiting Granule Secretion and Blocking the Phosphorylation of Extracellular-Signal-Regulated Kinase and Akt.

Authors:  Dong-Seon Kim; Hyun Dong Ji; Man Hee Rhee; Yoon-Young Sung; Won-Kyung Yang; Seung Hyung Kim; Ho-Kyoung Kim
Journal:  Evid Based Complement Alternat Med       Date:  2014-02-19       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.